Argentine Cancer Treatment: Cold Virus Attack on Colorectal Cancer
- Here's a breakdown of the key data from the provided text, focusing on the new cancer treatment:
- Oncolytic viruses are genetically engineered viruses that selectively infect and destroy cancer cells without harming healthy tissues.
- * Targets Cancer Heterogeneity: This is the first oncolytic virus specifically designed to combat the genetic diversity within tumors.
Here’s a breakdown of the key data from the provided text, focusing on the new cancer treatment:
What is it?
* A novel oncolytic virus (AOL) called AR2015. Oncolytic viruses are genetically engineered viruses that selectively infect and destroy cancer cells without harming healthy tissues.
* It’s based on a common adenovirus but has been significantly modified.
What makes it different/critically importent?
* Targets Cancer Heterogeneity: This is the first oncolytic virus specifically designed to combat the genetic diversity within tumors. Cancer cells within a single tumor aren’t all the same; this virus aims to overcome that resistance.
* Hybrid Promoter: The key innovation is replacing a crucial part of the virus (the promoter regulating its multiplication) with a tumor-specific hybrid promoter. This “genetic switch” is activated only in cancer cells.
* Expanded Range of Attack: The hybrid promoter is made of fragments from the A33 and vWA2 genes.This broadens the number of cancer cells the virus can target, as at least one of these genes is active in all tested samples.
* Synergy with Chemotherapy: The virus is more effective when combined with low doses of chemotherapy, and in some cases, led to complete tumor eradication.
How does it work?
* Intravenous Governance: The virus is delivered through an IV.
* Selective Replication: It multiplies only within malignant cells, causing them to die.
* Infiltration: The virus infiltrates tumors and destroys them from within.
What has been shown so far?
* Animal Models: AR2015 eliminated liver metastases from colorectal cancer in animal models.
* Patient Samples: The A33 and vWA2 genes were active in all primary tumors and metastases tested from patients with colorectal cancer.
* Potential for broader application: The researchers believe it could be applied to other gastrointestinal tumors.
Context & Future Outlook:
* Oncolytic viruses are gaining acceptance in cancer therapy, with several already approved for use in various countries (US, Europe, Japan, China).
* This Argentine advancement represents a significant advancement in the field, specifically in addressing tumor heterogeneity.